# Nova Minerals (NVA): A Short Seller Flags a 10-K/A Insider Cut; Critics Say the Units Do Not Match > Spruce Point Capital (@sprucepointcap) says a Nova Minerals (NYSE American: NVA) 10-K/A shows the largest insider and finance director cut holdings from about 2.26 million to 0.43 million shares after token director buys and fresh Alaska permits. A critic replies that CDI and common-share units were mixed. We check both claims against the short campaign and the permit news. By MCAFax · Published November 5, 2026 Section: Markets & Main Street › From Wall Street · Series: Market Calls, Investigated (https://mcafax.com/notebook/series/market-calls-investigated) Canonical: https://mcafax.com/notebook/nva-nova-minerals-10ka-insider-cut-vs-cdi-unit-debate Source: MCAFax, The Broker's Notebook (https://mcafax.com/notebook). MCAFax is not a lender or a law firm. --- Nova Minerals Corp (NYSE American / ASX: NVA) is back in a forensic fight. Spruce Point Capital (@sprucepointcap) says a new 10-K/A shows the largest insider and Director of Finance cut a large stake just as Alaska antimony permits arrived. A critic says the short seller compared CDIs with common shares. We lay out both claims, the permit catalyst and Spruce Point's longer short campaign. *This is journalism and commentary, not investment advice. We hold no position unless stated.* ## Key facts - **Ticker and exchange:** Nova Minerals Corp, NVA, NYSE American (also ASX: NVA). - **Situation type:** Activist forensic short versus a junior antimony and gold developer. - **The call:** Spruce Point is short NVA; on October 29, 2026 it highlighted what it reads as a large insider reduction in a 10-K/A. - **Price:** NVA closed at $3.45 on October 28, 2026 (last close before that post) and about $4.52 on November 5, 2026. - **Permit news:** On October 27, 2026 Nova said it secured final permits for its Alaska antimony project, clearing a path toward 2027 production (company GlobeNewswire release). - **Token buys Spruce notes:** Recent open-market purchases by directors and the CEO (Form 4s in mid/late October) were small relative to the alleged cut. - **Debate:** StockSoftEng says 3,616,669 CDIs versus 436,806 common shares (including options) are different units at 12 CDIs per share, so there was "No sale." ## Did the largest insider really sell? Spruce Point's October 29 [post](https://x.com/sprucepointcap/status/2115866315433148913) applauds small director buys, then says the 10-K/A shows the largest insider and Director of Finance "appears to have sold a substantial position," "down from 2.26M to 0.43M" since end-September 2026 and "well below the 4.3M shares he owned in Sept '25," timed after permit news. It also notes the new CFO owns no stock. On October 31, StockSoftEng [replied](https://x.com/StockSoftEng/status/2116496210244866123): "3,616,669 is CDIs; the 10-K/A's 436,806 is common shares incl. 135,416 options. At 12 CDIs per share, 301,390 x 12 = 3,616,680. No sale." Spruce Point thanked the critic for clarifying in a short reply. Readers should compare the 10-K/A beneficial-ownership footnotes with ASX CDI disclosures rather than treat either tweet as final. ## What else is on the table? Spruce Point launched a detailed short report on February 20, 2026 titled around a "critical evaluation," estimating material downside and questioning infrastructure, weather, community pushback and commercial timelines. Nova published an ASX/SEC response arguing many points were historical or irrelevant and highlighting a U.S. Department of War award of about $43.4 million for domestic antimony. The October 27 permit release is the latest company catalyst shorts must underwrite. Public Form 4 summaries for late October show small open-market buys by CEO Christopher Gerteisen and directors, not large sales - which is consistent with Spruce Point calling those buys "token" while still alleging a larger beneficial-ownership drop in the amended annual report. ## Who's making this call and why? Spruce Point Capital, founded by Ben Axler, specializes in forensic short-selling. On our [scoreboard](https://mcafax.com/notebook/market-calls-scoreboard) it is 11-6 (.647) on 17 scored career calls, average edge about +10.4 points, with shorts 11-6 and last 10 at 6-4. Rank 3 in the career long-term view we publish. The October 29 note is a position update inside an open short, not a new initiation. Earlier October posts from the firm also pressed IperionX and Bunge; those tickers were already featured separately and are not re-featured here. **Other voices:** Critical-minerals traders still list NVA among antimony names to watch. That is momentum color, not a scored forensic rebuttal. StockSoftEng's unit critique is the clearest public pushback on the specific 10-K/A claim. ## Who disagrees? - **StockSoftEng:** unit mismatch (CDI vs common) explains the headline drop; "No sale." - **Nova Minerals:** February response to the original short report; October permit and production-path messaging. - **Form 4 tape:** recent disclosed trades are small buys, which bulls read as confidence and Spruce Point reads as optics. ## What are the key facts to verify? - Beneficial ownership tables in the latest 10-K/A versus ASX CDI registers for the same person. - Whether any Form 4 sale matches the alleged cut. - Status of Alaska permits, DoW funding conditions and 2027 production milestones. - Cash runway versus Spruce Point's claim the company has been running hot on cash. ## What would prove it right or wrong? Signals the short is working: - Confirmed open-market insider selling, funding stress, or permit/DoW setbacks. - Continued restatements or disclosure corrections that validate forensic claims. Signals it is failing: - Clean reconciliation showing no economic sale, plus funded progress to 2027 production. - Sustained insider buying that is large relative to float, not token. *This is journalism and commentary, not investment advice. We hold no position unless stated.* ## Questions readers ask **Is Nova Minerals (NVA) stock a good bet after the 10-K/A debate?** It depends on whether you trust Spruce Point's reading of beneficial ownership or the CDI-versus-common-share rebuttal. NVA closed at $3.45 on October 28, 2026 before Spruce Point's post and about $4.52 on November 5, 2026. The firm is short; Nova just highlighted final Alaska antimony permits. **What did Spruce Point claim about insiders?** On October 29, 2026 it said a 10-K/A shows the largest insider and Director of Finance cut holdings from about 2.26 million to 0.43 million shares since end-September, below 4.3 million in September 2025, after token director buys and permit news. It also said the new CFO owns zero shares. **What is the CDI critique?** StockSoftEng replied that 3,616,669 CDIs equal about 301,390 common shares at 12 CDIs per share, matching the 10-K/A's common-share figure once options are considered, so there was no sale. Spruce Point publicly thanked the critic for clarifying. **What permit news arrived in late October?** Nova's October 27, 2026 GlobeNewswire release said it secured final permits for its Alaska antimony project, clearing a path toward 202 **Who is Spruce Point Capital?** An activist forensic short seller founded by Ben Axler. In our tracking it is 11-6 on 17 scored calls at 180 days versus the S&P 500, average edge about +10.4 points, shorts 11-6. **Is this a new short initiation?** No. Spruce Point published a detailed NVA short report on February 20, 2026. Nova responded on the ASX/SEC. The October 29 post is an update inside that campaign. **Do Form 4 filings show big sales?** Late-October Form 4 summaries widely reported are small open-market purchases by the CEO and directors. That does not by itself settle the 10-K/A beneficial-ownership debate. **What would prove the short right?** Documented economic insider selling, funding stress, or permit/Department of War setbacks that cut the antimony path. **What would prove the short wrong?** A clean unit reconciliation with no sale, plus funded execution toward 2027 production and larger insider buying. **Does this piece recommend shorting or buying NVA?** No. This is journalism about a public short update and a public rebuttal. It is not a buy or sell recommendation.